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erelin (G) and triptorelin (T) for Russian health care system. METHODS: A review
was conducted to collect available evidence of the clinical efficacy and safety of L in
comparison with G and T. Cost-minimization analysis was performed. Direct costs
of treatment with studied drugs were considered for each option: cost for 1- year
hormonal therapy in a hypothetical cohort of 100 patients with PC. The calculation
of costs was based on drugs’ pries from the List of Vital and Essential Drugs in
Moscow region. In addition we made an estimate of the number of extra patients
who could have been treated if a less expensive alternative had been applied.
One-way sensitivity analysis was made. RESULTS: According to available pub-
lished data LHRH agonists have similar clinical efficacy and safety that allowed us
to use cost-minimization method. Costs for the medications in a hypothetical co-
hort of 100 patients with PC were equal to 290.263; 332.690 and 391.595 USD per year
for L, G and T respectively. When L is used instead of G and T extra 14 and 34
patients can be treated with LHRH for 1 year respectively. Sensitivity analysis has
shown, that L is less expensive if its price is no more than 14,6 % and 34,91%
from baseline when compared to G and T respectively. CONCLUSIONS: L-based
therapy has equal clinical efficacy comparing to the other LHRH analogues and is
on average a cost saving option when compared with G and T.
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OBJECTIVES: This study analyzed the cost-utility of everolimus  exemestane
(EVEEXE) versus placebo  exemestane (PBOEXE) in patients with HR
HER2–ABC. METHODS: The phase III BOLERO-2 study randomized 724 patients
with HR HER2–ABC and recurrence or progression during/after nonsteroidal aro-
matase inhibitor therapy to EVEEXE or PBOEXE. A survival partition model was
developed to compare treatment with EVEEXE versus PBOEXE (UK health care
perspective). The 18-month median follow-up data on progression-free survival
and mortality were obtained from BOLERO-2. Weibull functions were used to ex-
trapolate trial data beyond the follow-up period. Utilities from published sources
were combined with trial data to calculate quality-adjusted life years (QALYs) as-
sociated with health state. Background health state costs (ie, non-intervention
costs) were applied to calculate incremental costs. RESULTS:At 18 months’ follow-
up, ABC patients on EVEEXE gained 1.33 life years (LYs) and 0.76 QALYs versus
1.27 LYs and 0.65 QALYs with PBOEXE. Background health state and adverse
event (AE) costs were £9,944 with EVEEXE versus £12,924 with PBOEXE. Exclud-
ing drug acquisition costs, use of EVEEXE resulted in cost savings of £2,980. When
trial data were extrapolated to 5 years, EVEEXE led to a gain of 3.05 LYs and 1.46
QALYs versus 2.57 LYs and 1.16 QALYs with PBOEXE. Background health state and
AE costs were £30,094 with EVEEXE versus £29,560 with PBOEXE. The incremen-
tal (non-intervention) cost was £534 (due to longer survival). CONCLUSIONS: These
additional analyses from the BOLERO-2 study show that compared with PBOEXE,
patients receiving EVEEXE experienced longer PFS, which translated to health
gains in terms of both LYs and QALYs. EVEEXE was associated with savings in
non-intervention costs over the initial trial period and a modest increase in non-
intervention costs over the extrapolated 5-year time horizon.
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OBJECTIVES: To assess cost-utility in Belgium of once-per-cycle primary prophy-
laxis (PP) with pegfilgrastim vs. no prophylaxis and vs. PP with daily granulocyte-
colony stimulating factors (G-CSF) filgrastim or lenograstim (11-days per label or 6-
days per common clinical practice) for reducing febrile neutropenia (FN) incidence
in women with primary breast cancer receiving chemotherapy carrying a 20% or
higher overall risk of FN. METHODS: A decision-analytic model was constructed
from a health care-payer perspective. Costs were from official Belgian list prices
(April 2012) or literature and included drugs, drug administration, FN-hospitaliza-
tions and FN-related medical costs. Effectiveness inputs in terms of relative risk
reduction (RRR) for FN were based on the most recently published meta-analysis
(Cooper 2011). Survival and utility inputs were obtained from available data for
breast cancer patients in the US (Lyman 2009) and the UK (Whyte 2011). Outcomes
included number needed to treat to avoid an episode of FN (NNT), and incremental
cost effectiveness ratio (ICER) in terms of cost per quality-adjusted life-years
(QALY). A univariate sensitivity analysis evaluated the robustness of the model.
RESULTS: Pegfilgrastim demonstrated the lowest NNT (4.69). In terms of cost-util-
ity, pegfilgrastim was dominant vs. 11-day filgrastim or lenograstim and was con-
sidered cost-effective vs. no prophylaxis (€24,675/QALY) and 6-day filgrastim
(€18,265/QALY) or lenograstim (€12,782/QALY). In a scenario analysis reducing the
prices of daily G-CSFs by 30%, pegfilgrastim remained cost-effective at a willing-
ness to pay threshold of €30,000. The sensitivity analysis revealed that most sen-
sitive variables were effectiveness (RRR), incremental utility values (LYs and
QALYs) and cost of G-CSFs, and demonstrated the overall model to be robust.
CONCLUSIONS: In a Belgian setting, pegfilgrastim offered the most cost-effective
approach to primary prophylaxis of FN. In the cost-utility analysis pegfilgrastim
primary prophylaxis was dominant vs. 11-day G-CSF primary prophylaxis and
cost-effective vs. no prophylaxis and 6-day G-CSF primary prophylaxis.
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OBJECTIVES: Based on an exploratory biomarker analysis in the Phase 3 RCT
LYM3001 Study that evaluated bortezomib combined with rituximab against ritux-
imab, in a biomarker positive population of relapsed/refractory follicular lym-
phoma (RRFL) patients (Coiffier et al 2011, ASH), a cost-utility analysis was con-
ducted from the UK NHS perspective. METHODS: A lifelong Markov model with
monthly cycles was designed in MS Excel 2007. Three health states were defined:
progression free, progression and death. Patients received active treatment for the
first 5 weeks in the progression free state and best supportive care in progression.
Progression free survival (PFS) probabilities were extrapolated from the random-
ized controlled trial. In the PSMB1 P11A C/G heterozygote and low CD68 expression
subgroup of RRFL patients, the median PFS improved from 9.1 to 16.6 months
(p0.0001) with bortezomib/rituximab vs. rituximab alone. This subgroup was
identified using laboratory tests. The total cost included the cost of drugs, admin-
istration, biomarker analysis, follow up, best supportive care, end of life care and
adverse events per health state. Utilities were state dependent and disutilities were
applied for adverse events. General mortality, unit costs and utilities were obtained
from the literature. Annual discounting of 3.5% was applied on costs and health
effects. The result measured the incremental cost (£ 2011) per quality adjusted life
year (QALY) gained. RESULTS: The combination bortezomib/rituximab yielded 9.76
QALYs vs. 8.41 for rituximab alone in biomarker positive RRFL patients. The pro-
jected total costs were £ 56,362 and £37,701, respectively. The resulting incremental
cost effectiveness ratio (ICER) was £13,774/QALY gained. The probabilistic sensitiv-
ity analysis indicated that the cost-effectiveness probability exceeded 55% at
£20,000/QALY. CONCLUSIONS: In RRFL patients with positive biomarkers, PSMB1
P11A C/G heterozygote and low CD68 expression, bortezomib/rituximab was com-
pared against rituximab and generated an ICER below £20,000/QALY gained. This
analysis shows how personalized medicine may maximize cost-effectiveness.
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OBJECTIVES: Metastatic renal cell cancer (mRCC) is becoming an important part of
Serbian health care expenditure due to its increasing incidence, inadequate pre-
vention methods and expensive pharmaceutical options for disease control. Of all
available treatment options, only sunitinib is currently reimbursed in Serbia. This
study aims to assess the cost-effectiveness of everolimus in comparison to best
supportive care in mRCC patients who failed to respond to treatment with
sunitinib. METHODS: A Markov model was designed with respect to the Serbian
treatment protocols and a health care perspective was taken. Transitions between
health states were enabled by time-dependent probabilities extracted from pub-
lished Kaplan-Meier curves for progression-free (PFS) and overall survival (OS). The
cohorts were followed over 18 cycles, each cycle lasting 8 weeks, which covers the
life-time horizon of mRCC patients. An annual discount rate of 1.5% for health and
4% for costs was applied. One-way and probabilistic sensitivity analyses (PSA) were
performed to test the robustness and uncertainty around the base-case estimate.
RESULTS: The incremental cost-effectiveness ratio (ICER) for everolimus was esi-
mated at 64,028€/QALY. Sensitivity analysis identified the probabilities of OS and
PFS as the main drivers of the cost-effectiveness of everolimus. The cost of everoli-
mus and the utilities estimates were also of significant influence. PSA revealed a
wide 95% confidence interval around the base-case ICER estimate (36,147 - 186,053
€/QALY). Additionally, at a threshold of 14,400€/QALY (three times the GDP per
capita in Serbia) everolimus did not have probability of being cost-effective.
CONCLUSIONS: Base-case ICER was significantly higher than the commonly used,
GDP-based threshold, recommended by WHO, indicating that everolimus would
most likely be a cost-ineffective treatment in Serbian setting. However, prior to a
final decision on the acceptance/rejection of everolimus, reassessment of the
whole therapeutic group might be needed to constitute reasonable treatment strat-
egies within the mRCC field.
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OBJECTIVES: Examine the incremental costs of absenteeism and short-term dis-
ability associated with colorectal cancer (CRC). METHODS: The MarketScan Com-
mercial Claims and Encounters (CCAE) and Health and Productivity Management
(HPM) databases were used to identify patients age 18-64 diagnosed with CRC, with
first such date identified as the index date. Patients were also required to have
continuous insurance coverage and be included in the HPM database from 6
months prior through 12 months post index date. These cases were matched 1:1
without replacement based upon age, sex, and region of residence and controls
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were assigned an identical index date as their matched case. Absenteeism costs in
the 1 year post diagnosis were then estimated using a generalized linear model
with log link and variance function determined by modified Park test (GLM). Short-
term disability costs were estimated with a two part model where the first part
utilized a logistic model to determine the probability of having a short-term dis-
ability claim and the second part is a GLM model for patients who had such a claim.
The analyses controlled for patient characteristics, prior medical costs, and general
health. RESULTS: Patients with colorectal cancer in this study (N165) were mostly
male (75.76%) with a mean age of 52 years. Patients with colorectal cancer were
significantly less likely to be insured via point-of-service insurance (45.45% v
79.39%; p0.0001) but more likely to be insured via a preferred provider organiza-
tion (44.24% v 7.88%; P0.0001) compared to their healthy matches (N165). After
controlling for patient characteristics, prior medical costs and general health, pa-
tients with colorectal cancer experienced, on average, $6,075 higher short-term
disability costs (P0.0001) and $3,633 higher absenteeism costs (P0.0001) in the 1
year post diagnosis of CRC. CONCLUSIONS: Results indicate that CRC is associated
with significant work-related productivity loss costs in the first year post diagnosis.
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OBJECTIVES:To assess the costs of drugs for treatment of oncologic diseases (using
the example of hematologic malignancies) in the Ukrainian market and to explore
if there is a correlation between cost per daily-defined dose (DDD) and governmen-
tal purchase decisions. METHODS: Documentary analysis (market prices and hos-
pital purchases) was conducted, analyzing the following resources: hospital cards
(to define the most frequently used drugs for treatment of hematologic malignan-
cies and DDD), hospital drugs purchases 2011 (to define the list, quantities, and
prices of drugs purchased by the state), market prices by distributors and the state
registered prices (to define the median, minimum and maximum prices possible
for the market). RESULTS: Drugs that were frequently used and had the minimum
price per DDD were corticosteroids (dexamethazone, prednizolone), thalidomide,
lomustine, chlorambucil (used for elderly patients with CLL). The correlation be-
tween the amount of packs purchased by the government and cost per DDD paid
was -0.310, indicating that there is a low correlation between price increase and the
state purchased decrease. Several cases when the state purchased two brand
names for one generic product with extreme difference in price/mg were observed.
CONCLUSIONS: State purchases in Ukraine have a tendency to include cheaper
drugs in the higher amounts than more expensive ones. Though, not all of the
decisions have only a price reasoning. The reasons for purchases of different brand
names for one generic product should be provided.
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OBJECTIVES:Due to advances in medical technology, cancer care costs are growing
rapidly and expenditures with oncology treatment represents a significant burden
for managed care organizations. Therefore, the study aims to evaluate the profile of
oncology patients and treatment costs from UNIMED São José do Rio Preto (USJRP),
a medical cooperative responsible for approximately 118,000 lives in São Paulo,
Brazil. METHODS: A review of USJRP administrative claims database was con-
ducted for patients who were under any cancer treatment between January 2011 to
December 2011. Data regarding gender, age and treatment expenditures were as-
sessed for the entire period. Only costs associated with treatment were taken into
account (i.e. drugs, devices/materials and room taxes). Type of cancer was identi-
fied according to ICD-9 codes and grouped into major cancer types. Costs were
reported in Brazilian Reais (1.00US$2.00BRL Jun/2012). RESULTS: A total of 324
oncology patients were identified (44.0% male and 56.0% female) with overall ex-
penditures in the study period of BRL 4.57 million. Average age was 59.2 years (55.4
for female and 64.4 for male). Drugs accounted for 93.4% of all treatment expendi-
tures, followed by room taxes with 4.2%. Average treatment cost per patient was
BRL 14,105, being lymphoma the most expensive type of cancer (BRL 15,544 per
patient). In terms of overall costs, breast cancer represented 43.8% of all treatment
costs (BRL 1.98 million), followed by colorectal cancer (24.0%; BRL 1.10 million) and
lung cancer (12.0%; BRL 0.55 million). CONCLUSIONS: More than 300 patients were
treated for cancer in 2011 which accounted for approximately BRL 4.57million,
being drugs responsible for more than 90% of all treatment expenditures. In 2011,
health care costs reported for USJRP was BRL 217,849,541 (average of BRL 1,850 per
life), demonstrating that costs associated with oncology treatment are high and
suggesting the importance of economic evaluation of cancer drugs for the decision
making process.
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OBJECTIVES: Oral chemotherapy agents are increasingly used for cancer treat-
ment. The study objective was to quantify abandonment and reversal rates of oral
oncolytics in patients filling prescriptions from traditional retail, Medco specialty,
and other specialty pharmacies. Prescriptions are abandoned for different reasons
including cost-sharing amounts and complexity of regimens prescribed.
METHODS: Using a retrospective cohort design, we selected patients aged 18
years with a prescription for erlotinib, capecitabine, or imatinib during 2007-2011
from a Medco population of U.S. commercial and Medicare health plans. These
agents represent widely available oral oncolytic agents. Patients were classified
according to initial oncolytic received and pharmacy channel providing the medi-
cation. Abandonment was defined as a reversal following initial approval of pre-
scription with no additional paid claims for the agent within 90 days of reversal.
Overall reversal rates representing potential challenges filling prescriptions were
also examined. Reversals occur for various reasons including incorrect information
on claim or inability of patient to pay cost-sharing amount. RESULTS: Among
patients treated with an oral oncolytic, 10,297 were prescribed erlotinib, 20,062
were prescribed capecitabine and 7,233 were prescribed imatinib. Mean age was
69.1, 61.3, and 62.1 years for erlotinib, capecitabine, and imatinib users, respec-
tively. The abandonment rate of the initial oncolytic was 1.9%, 1.6%, and 1.2% for
erlotinib, capecitabine, and imatinib, respectively. The rate of reversals was 4.9%,
3.7%, and 3.5% for erlotinib, capecitabine, and imatinib, respectively. For oncolytics
examined, Medco specialty channel (0.2%) had lowest rates of abandonment ver-
sus other specialty (1.7% P0.001) and retail (2.0% P0.001). In multivariate models
controlling for age, gender, and geographic region, specialty channel was signifi-
cantly associated with filling the index prescription without challenges for all
oncolytics. CONCLUSIONS: Low abandonment rates were observed in this study.
The pharmacy channel in which patients fill their index oral oncolytic appears to
be influential on patient abandonment rates.
PCN106
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OBJECTIVES: High rates of compliance and persistence to medical treatments are
associated with improved patient outcomes. Breast cancer survival has signifi-
cantly increased, compliance with adjuvant treatment is very importance to en-
sure optimal treatment outcome. In this analysis, persistence i.e. the extent to
which patients continue treatments was estimated for breast cancer patients on
tamoxifen (TAM) and aromatase inhibitors (AI) treatment in primary care practices
in Germany.METHODS: This retrospective cohort study analysed longitudinal rou-
tine care data collected by gynaecologists and general practitioners in Germany
(IMS® Disease Analyzer). Non-persistence was defined as a period of 180 days
without prescriptions. The lack of persistence was compared using Cox regression
models after adjusting for age, gynecologist care, private health insurance, urban
residency, practice in West-Germany, defined co-diagnoses and co-therapies (i.e.
bisphosphonates). RESULTS: We included 12,412 patients diagnosed with primary
breast cancer and first-time prescriptions of hormone therapy. A total of 7312
patients started with TAM (mean age 62.1 (SD: 13.5)), 5,100 with AI (anastrozole,
exemestane, letrozole) (mean age 66.4 (SD: 10.6) as first line treatment. After 3 years
42.1% of TAM-patients and 40.2% of AI-patients in German practices discontinued
their treatment. In the adjusted Cox model treatment in gynaecologist practice (HR:
0.46, p0.001), age over 70 (HR 0.90, p0.010), change of hormone therapy sub-
stance (HR: 0.82, p0.001), co-therapy with bisphosphonates (HR: 0.86, p0.013)
and diagnosis of diabetes mellitus (HR: 0.82, p0.001) were associated with a lower
risk of discontinuation of therapy. No significant effect was found for western
Germany, urban residency, private insurance status and other age groups.
CONCLUSIONS: Long-term persistence on hormonal treatment in women with
endocrine-responsive breast cancer is low. Factors affecting treatment discontin-
uation need to be identified and properly addressed. Patients at high risk of non-
adherence to the prescribed medication should be cared for in more individualised
fashion to ensure optimal treatment outcome.
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OBJECTIVES:Metastatic renal cell carcinoma (mRCC) has a very high mortality rate
with a 5 year survival of 5-15%. With the approval and use of a number of oral
agents in the first line, treatment conditions for mRCC patients have significantly
improved. Objective of this study was to evaluate the persistence in the first line
treatment of mRCC patients in Germany.METHODS: The present study is based on
the IMS LRx database containing 80% of all prescriptions reimbursed by the Ger-
man statutory health insurance with an anonymized patient ID. The data base
covers longitudinal information on patient level, such as age, gender, insurance
company, region as well as prescriber specialty, date and medication on package
level. Persistence was defined as the number of days from the date of the first
prescription until the date of the last prescription plus the number of daily dosages
prescribed. RESULTS: A total of 2799 patients starting first line treatment in mRCC
between January 2010 and September 2010 were identified based on medication,
co-medication and dosage. Median persistence in days was 84 for patients receiv-
ing Temsirolimus (T; n384), 103 for Sorafenib (So; n368), 117 for Pazopanib (P;
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